Trial Profile
A Single-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3113593 in Healthy Subjects and Patients With Chronic Kidney Disease Treated With Hemodialysis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 Jan 2019
Price :
$35
*
At a glance
- Drugs LY 3113593 (Primary) ; LY 3113593 (Primary)
- Indications Renal failure
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 04 Sep 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 04 Dec 2014 Planned End Date changed from 1 Sep 2015 to 1 Oct 2015 as reported by ClinicalTrials.gov record.
- 04 Dec 2014 Planned primary completion date changed from 1 Sep 2015 to 1 Oct 2015 as reported by ClinicalTrials.gov record.